Togo Malaria Vaccine: Protecting 269,000 Children
- The West African nation becomes the 22nd in africa to adopt the R21/Matrix-M vaccine, targeting nearly 270,000 children in a thorough rollout.
- Togo officially launched its national malaria vaccination program on September 1, 2025, integrating the R21/Matrix-M vaccine into its routine immunization schedule.
- Malaria is a leading cause of illness and death in Togo, disproportionately affecting children under five.
“`html
Togo Launches Nationwide R21 Malaria Vaccine Program
Table of Contents
The West African nation becomes the 22nd in africa to adopt the R21/Matrix-M vaccine, targeting nearly 270,000 children in a thorough rollout.
What Happened?
Togo officially launched its national malaria vaccination program on September 1, 2025, integrating the R21/Matrix-M vaccine into its routine immunization schedule. The Health Ministry announced the initiative during a press conference on Tuesday, outlining plans to reach approximately 269,000 children across all 39 health districts in the country. This marks a notable escalation in Togo’s efforts to combat the pervasive disease.
Why This Matters: A Public Health Milestone
Malaria is a leading cause of illness and death in Togo, disproportionately affecting children under five. The introduction of the R21 vaccine represents a crucial step towards achieving the government’s enterprising goal of eliminating malaria’s burden by 2030, allowing communities to focus on economic and social development. This initiative aligns with the World Health Institution’s (WHO) recommendations and global efforts to accelerate malaria control.
Understanding the R21/Matrix-M Vaccine
The R21/Matrix-M vaccine, developed by the University of Oxford and manufactured by the Serum Institute of India, has demonstrated promising efficacy in clinical trials. It is the world’s first malaria vaccine to meet the WHO’s required 75% efficacy threshold. Unlike previous malaria vaccines, R21/Matrix-M requires fewer doses and is more affordable, making it a viable option for large-scale vaccination programs in resource-limited settings.
| vaccine feature | Details |
|---|---|
| Developer | University of Oxford |
| Manufacturer | Serum Institute of India |
| Efficacy | Reported efficacy exceeding 75% in clinical trials. |
| Dosage | Typically a three-dose schedule. |
Togo’s Malaria Landscape: A Closer Look
Malaria transmission in Togo is perennial, meaning it occurs year-round, but peaks during the rainy season (typically april to November) due to increased mosquito breeding.In 2022,children under five accounted for 64% of confirmed malaria cases and 32% of malaria-related deaths,highlighting the vulnerability of this age group.The country has been implementing other malaria control measures, including insecticide-treated bed nets (ITNs) and indoor residual spraying (IRS), but vaccination is expected to provide an additional layer of protection.
Collaboration and Funding
The Togolese government is working in close partnership with several key organizations to implement the vaccination program. These include the World Health Organization (WHO), UNICEF, Gavi, the Vaccine Alliance, and other technical and financial partners. Gavi, the Vaccine Alliance, is providing significant financial support for vaccine procurement and delivery, while UNICEF is assisting with logistics and supply chain management. The WHO is providing technical guidance and monitoring the program’s impact.